PRABJEET KAUR: Open Payments
NPI 1881469179 · RIVERDALE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 59 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $854 · 2025 $1,636
Food & beverage: $1,636
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 17 | $503 |
| AstraZeneca Pharmaceuticals LP | 7 | $410 |
| Novartis Pharmaceuticals Corporation | 8 | $147 |
| GlaxoSmithKline, LLC. | 6 | $98 |
| Galderma Laboratories, L.P. | 1 | $95 |
| Lilly USA, LLC | 4 | $89 |
| Invivyd Inc | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Cycle Pharmaceuticals Inc | 2 | $34 |
Products named: DUPIXENT, TEZSPIRE, Rhapsido, NEMLUVIO, EBGLYSS, NUCALA, PEMGARDA, HYQVIA.
Industry payments across NJ — which companies pay providers there.
